spacer
home > white papers > Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands - West Pharmaceutical Services, Inc.
WHITE PAPERS
logo_West_Pharm6.jpg

West Pharmaceutical Services, Inc.

phone America +1 610 594 2900
web http://www.westpharma.com
email 530 Herman O. West Drive Exton, PA 19341

Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands

The current pharmaceutical market has faced a variety of challenges, including increasing expectations for quality from end-users and regulatory agencies driven by concern for patient safety. While pharmaceutical companies are working to assure that new quality and compliance paradigms are met, a balance must be achieved between the reality of managing costs in an effort to provide a product that meets the requirements of payers along with facilitating profitability in order to continue adequate business reinvestment.
Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Sensitech Inc. Marks 30th Anniversary and Introduces New SensiWatchTM Platform for End-to-End Real-Time In-Transit Visibility

Beverly, MA, June 22, 2020 – For 30 years, Sensitech Inc. has helped leading companies in the food, pharmaceutical, industrial and consumer goods segmentsdeliver higher-quality products, ensure consumer safety, comply with rigorous regulatory requirements, protect brand equity, and increase profitability. Today,Sensitech builds on this legacy with the announcement of a new state-of-the-art, end-to-end,real-time in-transit visibility solution –the SensiWatchTMPlatform.Sensitech is part of Carrier Global Corporation (NYSE: CARR), a leading global provider of innovative heating, ventilating and air conditioning (HVAC), refrigeration, fire, security and building automation technologies.
More info >>


White Papers

Accelerating the Time from DNA to Material

Merck

Cell line development is a critical step in upstream process development for monoclonal antibodies (mAbs). Unfortunately, the search for the bestproducing clone can be labor- and resource-intensive and is often compared with looking for a needle in a haystack. Cells must first be engineered to produce the biologic of interest and the cell line generated from a high producing clone must deliver a sufficiently high titer to support clinical studies, and ultimately commercialization of the therapeutic.
More info >>


Industry Events

Outsourcing in Clinical Trials Europe

26-27 October 2020, Paris, France

Arena International are delighted to announce the return of Outsourcing in Clinical Trials Europe. Part of our global series of events, this flagship show will attract the leading clinical professionals from across Europe. The 10th Annual event will be hosted in Paris.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement